End-of-day quote
Shanghai S.E.
18:00:00 2024-05-14 EDT
5-day change
1st Jan Change
29.55
CNY
-1.50%
-8.66%
-28.01%
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
February 28, 2024 at 06:31 am
Beijing Hotgen Biotech Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 541.15 million compared to CNY 3,556.55 million a year ago. Net income was CNY 30.16 million compared to CNY 944.74 million a year ago.
Basic earnings per share from continuing operations was CNY 0.34 compared to CNY 10.33 a year ago.
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-29
CI
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan
04-16
MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.
04-02
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
02-28
CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.
02-07
CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.
02-06
CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index
12-18
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index
23-09-18
CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors
23-09-10
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-29
CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.
23-06-15
CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million.
23-06-12
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.
23-04-06
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-27
CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.
23-01-04
CI
Beijing Hotgen Biotech Unit Secures Registration Certificate For Two Devices
22-12-22
MT
Beijing Hotgen Biotech Gets Registration Certificate for Hepatitis B Assay Kit; Shares Fall 4%
22-11-16
MT
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-24
CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.
22-10-11
CI
Beijing Hotgen Biotech’s Board Approves Up to $43 Million Share Buyback
22-09-07
MT
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.
22-09-06
CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.
22-09-05
CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.
More about the company
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**